Skip to main content

Access important information about the Children and Families Specialty Plan (CFSP) that launched December 1, 2025.

Provider Central Search

Use the search function below to search Provider Central

Alliance Behavioral Health Clinical Guidelines

Alliance’s approved Clinical Practice Guidelines and Psychological Testing Guidelines document what is known and what is not known about a condition or disorder for the treatment of patients with the ultimate goal of improving care.

Clinical Practice Guidelines have been developed nationally and internationally by a variety of expert sources including the American Psychiatric Association (APA), American Academy of Child and Adolescent Psychiatry (AACAP), American Society of Addiction Medicine (ASAM), Substance Abuse and Mental Health Services Administration (SAMHSA) and other national and international societies, government/VA/DoD, and other care delivery systems such as Magellan and Managed Care organizations (MCOs).

When national guidelines are unavailable, work groups comprised of Alliance staff, providers and consultants who are experts in their fields have developed clinical guidelines. All of these guidelines have been reviewed and adopted by the Alliance Clinical Advisory Committee to assist providers and consumers alike in the clinical decision making process for a variety of mental health and substance use disorders with the goal of improved patient management and enhanced quality of care. As a result of this explosion of knowledge, concerns about the quality of care, access and cost and to determine “appropriate” or “reimbursable” care, it is necessary to describe the range of treatments available for patients with Mental Illness, Behavioral Disorders and/or Substance Use Disorders.

Clinical Practice Guidelines clearly and concisely document what is known and what is not known about a condition or disorder for the treatment of patients with the ultimate goal of improving care. These guidelines reflect evidence based treatment, but are not intended to be service definitions, or medical necessity criteria, though they may overlap. Additionally, guidelines should enhance individualized care, sound clinical practice and good judgment. Guidelines also do not supersede federal and/or state regulations. Alliance will continue to review, revise and update its approved clinical practice guidelines. Your comments and suggestions are welcome.

Clinical Guidelines-Adult

Clinical Guidelines-Adult
Adult Mental HealthDiagnosisGuideline/LinkDeveloper/Source (Year)Notes/Additional Links
Antipsychotic Medication Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation 2024ADA, APA, AACN, NAASO (2004)
Benzodiazepine Tapering Clinical Practice Guideline on Benzodiazepine TaperingASAM (2024)
Bipolar DisorderF31Treatment for Bipolar Disorder in Adults: A Systematic ReviewAHRQ (2018) Bipolar Disorder: Assessment and Management (NICE, 2023)

Practice Guideline for the Treatment of Patients with Bipolar Disorder (APA, 2002)

Practice Guideline For The Treatment of Patients With Bipolar Disorder, 2nd ed. (Guideline Watch, 2005)

VA/DoD Clinical Practice Guideline for the Management of Bipolar Disorder (VA/DoD, 2010)
DementiaF02Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias

Guideline Watch: Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias
APA (2007)



2014 Guideline Watch (2014)
Practice Guideline: Use of Antipsychotics to Treat Agitation or Psychosis in Patients with Dementia (APA, 2016)

Dementia: Assessment, Management and Support for People Living with Dementia and Their Carers (NICE, 2018)
Eating DisordersF50Practice Guideline for the Treatment of Patients with Eating Disorders

Pocket Guide for the Treatment of Patients With Eating Disorders
APA (2023)


APA (2023)
Eating Disorder Standards for Behavioral Health Care (The Joint Commission, 2016)

Eating Disorders: Recognition and Treatment (NICE, 2017)
Generalized Anxiety Disorder (GAD)F41.1Generalised Anxiety Disorder and Panic Disorder in Adults: Management

Anxiety Disorders in Adults: Screening
NICE (2020)


USPSTF (2023)
Major Depressive DisorderF32, F33Management of Major Depressive DisorderVA/DoD (2022)
Obsessive-Compulsive DisordersF42Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder

Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
APA (2007)


APA Guideline Watch (2013)
Panic DisorderF41.0Generalised Anxiety Disorder and Panic Disorder in Adults: Management

Practice Guideline for the Treatment of Patients with Panic Disorder
NICE (2020)


APA (2009)
Post-Traumatic Stress DisorderF43.1Management of Posttraumatic Stress Disorder and Acute Stress DisorderVA/DoD (2023) Post-traumatic Stress Disorder (NICE, 2018)
SchizophreniaF20-F29Treatment of Patients With Schizophrenia

INTEGRATE: International Guidelines for the Algorithmic Treatment of Schizophrenia


APA (2020)

Lancet Psychiatry (2025)
Social Anxiety Disorder (Social Phobia)F40.10Social Anxiety Disorder: Recognition, Assessment and Treatment NICE (2013)
SuicideAssessment and Management of Patients at Risk for SuicideVA/DoD (2024)Preventing Suicide in Community and Custodial Settings (NICE, 2018)

Clinical Guidelines-Children and Adolescents

Clinical Guidelines-Children and Adolescents
Child/Adolescent Mental HealthDiagnosisGuideline LinkDeveloper/Source (Year)Notes/Additional Links
Antipsychotic MedicationPractice Parameter for the Use of Atypical Antipsychotic Medications in Children and AdolescentsAACAP 2011

Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth (2017)

Guidance on Strategies to Promote Best Practice in Antipsychotic Prescribing for Children and Adolescents (SAMHSA, 2019)
Attention Deficit Hyperactivity DisorderF90Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and AdolescentsAAP (2019) Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NICE, 2019)
Bipolar DisorderF31
Bipolar Disorder, Psychosis and Schizophrenia in Children and Young People

Practice Parameter for the Assessment and Treatment
of Children and Adolescents With Bipolar Disorder
NICE (2015)



AACAP (2006)
Eating DisordersF50Identification and Management of Eating Disorders in Children and AdolescentsAAP (2021) The American Psychiatric Association Practice Guideline for the Treatment of Patients with Eating Disorders (APA, 2023)
Generalized Anxiety DisorderF41.1Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Anxiety DisordersAACAP (2020)
Major Depressive DisorderF32, F33Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Major and Persistent Depressive DisordersAACAP (2023) Depression in Children and Young People: Identification and Management (NICE, 2019)
Obsessive-Compulsive DisorderF42Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Anxiety DisordersAACAP (2020) Practice Parameter for the Assessment and Treatment of Children and Adolescents with Obsessive-Compulsive Disorder (AACAP, 2012)
Oppositional Defiant DisorderF91.3Practice Parameter for the Assessment and Treatment of Children and Adolescents with Oppositional Defiant DisorderAACAP (2007)
Panic DisorderF41, F93 Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Anxiety DisordersAACAP (2020)
Post-Traumatic Stress DisorderF43Posttraumatic Stress DisorderAACAP (2023) Practice Parameter for the Assessment and Treatment of Children and Adolescents with Posttraumatic Stress Disorder (AACAP, 2010)
SchizophreniaF20, F25, F29Psychosis and Schizophrenia in Children and Young People: Recognition and ManagementNICE (2016) Practice Parameter for the Assessment and Treatment of Children and Adolescents with Schizophrenia (AACAP, 2013)
Sexualized BehaviorChildren with Sexual Behavior Problems

Practice Guidelines for Assessment, Treatment, and Intervention with Adolescents Who Have Engaged in Sexually Abusive Behavior
ATSA (2023)


ATSA (2017)

Clinical Guidelines-SUD

Clinical Guidelines-SUD
Substance Use DisorderDiagnosisGuideline LinkDeveloper/Source (Year)Notes/Additional Links
Alcohol Use DisorderF10Alcohol Withdrawal Management

Pharmacological Treatment of Patients with Alcohol Use Disorder
ASAM (2020)

APA (2018)
Nicotine Use Disorder (Adult)F17Clinical Interventions to Treat Tobacco Use and Dependence Among Adults

Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions
CDC (2024)


USPSTF (2021)
You Quit Two Quit

QuitlineNC

Implementing Tobacco Cessation Programs in Substance Use Disorder Treatment Settings (SAMHSA, 2018)

Implementing Tobacco Cessation Treatment for Individuals with Serious Mental Illness: A Quick Guide for Program Directors and Clinicians (SAMHSA, 2019)
Nicotine Use Disorder (Child/Adolescent)F17Tobacco Use in Children and Adolescents: Primary Care InterventionsUSPSTF (2020)Live Vape Free , a quit vaping program for NC young people aged 13-26

Talking with Your Teen About Vaping (SAMHSA)

Tobacco, E-cigarettes, and Vaping (SAMHSA, 2023)

Youth-Centered Tobacco Educational Resources (NCDHHS, 2024)

E-Cigarettes and Vaping (AACAP, 2023)
Opioid Use DisorderF11Opioid Use Disorder: Treating

National Practice Guideline for the Treatment of Opioid Use Disorder

Treatment Improvement Protocol 63: Medications for Opioid Use Disorder

Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl
CDC (2024)

ASAM (2020)


SAMHSA (2021)
R3 Report: Medications for Opioid Use Disorder (The Joint Commission, 2024)
Opioid Use Disorder in Pregnant and Parenting WomenClinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants

Opioid Use and Opioid Use Disorder in Pregnancy
SAMHSA (2018)




ACOG (2017)
Opioid Treatment Programs (OTPs)Federal Guidelines for Opioid Treatment ProgramsSAMHSA (2015)
Stimulant Use DisorderClinical Practice Guideline on the Management of Stimulant Use DisorderASAM/AAAP (2024)
SUD, general (Adult)Clinical Practice Guideline for the Management of Substance Use DisordersVA/DoD (2021)

Clinical Guidelines-I/DD

Clinical Guidelines-I/DD
Intellectual / Developmental DisabilityDiagnosisGuideline LinkDeveloper/Source (Year)Notes/Additional Links
ASDF84Identification, Evaluation, and Management of Children With Autism Spectrum DisorderAAP (2020) Autism Spectrum Disorder in Under 19s: Recognition, Referral and Diagnosis (NICE, 2017)

Practice Parameter for the Assessment and Treatment of Children and Adolescents with Autism Spectrum Disorder (AACAP, 2014)
AssessmentGuidelines for Assessment and Intervention with Persons with DisabilitiesAmerican Psychological Association (2022)Assessment of and Intervention With Persons With Disabilities
(Geared toward psychologists & testing, focuses broadly on disabilities.)
Developmental DisabilitiesF70-F73Integrated Mental Health Treatment Guidelines for Prescribers in Intellectual and Developmental DisabilitiesThe Center for START Services (2021)
Dual DiagnosisPractice Parameter for the Assessment and Treatment of Psychiatric Disorders in Children and Adolescents with Intellectual Disability AACAP (2020) MHDD Fact Sheets (Mental Health and Developmental Disabilities National Training Center)

Dual Diagnosis: Overview of Therapeutic Approaches for Individuals with Co-Occurring Intellectual/Developmental Disabilities and Mental Illness for Direct Support Staff & Professionals working in the Developmental Disability System (Ohio Mental Illness/Developmental Disability Coordinating Center of Excellence, 2013)

Guidelines for Understanding and Serving People with Intellectual Disabilities and Mental, Emotional, and Behavioral Disorders (Florida Developmental Disabilities Council, 2009)
Genetic Syndromes Cri du Chat Support Group

RECONNECT study on Fragile X Syndrome

Neurofibromatosis Network

Classical Homocystinuria, Maple Syrup Urine Disease, Phenylketonuria, Tyrosinemia, Organic Acidemias, and Urea Cycle Disorders

Prader-Willi Syndrome Association-NC Chapter

The 22q Family Foundation

Health Watch Tables for Selected Developmental and Related Disabilities
Primary CarePrimary Care of Adults with Intellectual and Developmental Disabilities - 2018 Canadian Consensus guidelinesDevelopmental Disabilities Primary Care Initiative (2018) Health Care for Adults with Intellectual and Developmental Disabilities - Toolkit for Primary Care Providers (Vanderbilt University Medical Center)
TBI Clinical Practice Guideline for the Management and Rehabilitation of Post-Acute Mild Traumatic Brain Injury and Provider Summary of same

Canadian Clinical Practice Guideline for the Rehabilitation of Adults with Moderate to Severe TBI
VA/DoD (2021)



Ontario Neurotrauma Foundation (2024)
Texas/Algorithm Project Determination of Intellectual Disability Best Practice Guidelines
(NB, for children, sections 1-7 helpful in determining IDD, testing guidelines, types of assessments, and report writing)
Texas Health and Human Services (2025)
Trauma Best Practices in Assessment and Treatment of Trauma for People with Intellectual and Developmental Disabilities Who Communicate Without Speech (Strategic Education Solutions, 2021)

Trauma and Trauma-Informed Practices (The Link Center, 2024)

The National Child Traumatic Stress Network (NCTSN)

Children with Intellectual and Developmental Disabilities (IDD) Who Have Experienced Trauma (NCTSN)

Tailoring Trauma-Focused Cognitive Behavioral Therapy for Youth with Developmental Disabilities (TF-CBT IDD) and Their Caregivers (STRYDD Center)

Implementing Trauma-Informed Care in IDD Organizations and Systems (Traumatic Stress Institute)

Psychological Testing

Psychological testing involves the use of formal procedures using reliable and valid instruments to measure the areas of intellectual, cognitive, adaptive, emotional and behavioral functioning along with personality styles, interpersonal skills and psychopathology. Prior to administering a battery of tests, it is important for the evaluator to gather (or review) updated clinical information. Relevant clinical information should be considered from the Comprehensive Clinical Assessment and/or most recent medical, psychiatric, and/or educational evaluations. The evaluator should consider historical clinical information, identify specific questions to be addressed by the evaluation, and determine that the clinical questions cannot be addressed through a diagnostic interview with a skilled clinician.

The evaluator should inquire about and review any prior psycho-educational, psychological, developmental and neuropsychological testing that may have been administered and request copies for review prior to conducting a new battery. If prior testing cannot be reviewed, the provider should document their attempts to access the information and offer an explanation pertaining to the clear medical necessity for a new assessment. Attempts should be made to determine when tests were previously administered to ensure that test exposure is not a factor in the outcome of the evaluation.

The evaluator should take note on the dates of administration and whether questions presented for testing have been addressed in a prior evaluation. The evaluator should be conscious of factors that may interfere with the validity of outcomes including recent exposure to a standardized test, active substance use/abuse, vision or hearing impairments, health and/or medication related concerns. Testing related to the treatment of pain or as a component of a pre-surgical evaluation may be considered medically necessary if consistent with the expectations per policy.

It is expected that the request for testing may include information regarding prior screening and assessment, prior intervention for the given diagnosis, an explanation pertaining to why the clinical evaluation was inconclusive, and a statement regarding the need for psychological testing to clarify the diagnosis. Tests must be standardized and validated measures recognized by the scientific and professional community as a national standard for professional practice. Practitioners administering psychological batteries should practice within their scope and be credentialed in a manner consistent with the expectations of the North Carolina Psychology Board.

Developmental Testing

Developmental testing involves the use of standardized and validated measures to explore developmental concerns for individuals who may have been identified through the use of screening tools. Tests included in a developmental battery focus on cognitive, language, motor, and socio-emotional development. The findings of these evaluations can assist in identifying children who may have developmental delays and developing targeted intervention plans to support them in making gains. The evaluator should be conscious of factors that may interfere with the validity of outcomes including: recent exposure to a standardized test, vision or hearing impairments, health and/or other related concerns.

Prior to administering a battery of tests, it is important for the evaluator to gather (or review) relevant information. Relevant clinical information should be considered from the Comprehensive Clinical Assessment and/or most recent medical, psychiatric, and/or educational evaluations. The evaluator should consider historical clinical information, identify specific questions to be addressed by the evaluation, and determine that the clinical questions cannot be addressed through a diagnostic interview with a skilled clinician.

The evaluator should inquire about and review any prior psycho-educational, psychological, developmental, and neuropsychological testing that may have been administered and request copies for review prior to conducting a new battery. If prior testing cannot be reviewed, the provider should document their attempts to access the information and offer an explanation pertaining to the clear medical necessity for a new assessment.  Attempts should be made to determine when tests were previously administered to ensure that test exposure is not a factor in the outcome of the evaluation. The evaluator should take note on the dates of administration and whether questions presented for testing have been addressed in a prior evaluation.

It is expected that the request for testing may include information regarding prior screening and assessment, any prior intervention, an explanation pertaining to why the clinical evaluation was inconclusive, and a statement regarding the need for developmental testing to clarify the diagnosis. Tests must be standardized and validated measures recognized by the scientific and professional community as a national standard for professional practice. Practitioners administering psychological tests (within developmental batteries) should practice within their scope and be credentialed in a manner consistent with the expectations of the North Carolina Psychology Board.

Neuropsychological Testing

Neuropsychological testing involves the use of formal procedures using reliable and valid instruments to detect the existence of brain damage, dysfunction, injury, and/or functional deficits associated with the deterioration of brain function related to a condition or medical disease process. Prior to administering a battery of tests, it is important for the evaluator to gather (or review) updated clinical information. Relevant clinical information should be considered from the Comprehensive Clinical Assessment and/or most recent medical, psychiatric and/or educational evaluations. The evaluator should consider historical clinical information, identify specific questions to be addressed by the evaluation, and determine that the clinical questions cannot be addressed through a diagnostic interview with a skilled clinician.

The evaluator should inquire about and review any prior psycho-educational, psychological, developmental and neuropsychological testing that may have been administered and request copies for review prior to conducting a new battery. If prior testing cannot be reviewed, the provider should document their attempts to access the information and offer an explanation pertaining to the clear medical necessity for a new assessment. Attempts should be made to determine when tests were previously administered to ensure that test exposure is not a factor in the outcome of the evaluation. The evaluator should take note on the dates of administration and whether questions presented for testing have been addressed in a prior evaluation.

Testing related to the treatment of pain or as a component of a pre-surgical evaluation may be considered medically necessary if consistent with the expectations per policy. Prior to a neuropsychological evaluation, a clinical evaluation should have been completed and found to be inconclusive. Physicians may refer patients with suspected or known cognitive deficits for neuropsychological testing to quantify their cognitive and behavioral capabilities. Common measures used in neuropsychological batteries include tests of cognitive functioning, attention, language, motor, achievement and personality.

Neuropsychological tests are used to clarify the patient’s diagnosis in instances where the patient presents with atypical symptoms, a behavioral health condition or a medical condition. The tests are also used to establish a baseline of neurocognitive functioning, monitor changes from baseline in functioning, and to assist with treatment, placement, and/or discharge planning. Neuropsychological testing may be considered medically necessary for patients diagnosed with ADHD when medical screenings (including the use of screening tools used by an MD) support further assessment of specific neurocognitive behavioral deficits.

The evaluator should be conscious of factors that may interfere with the validity of outcomes including: recent exposure to a standardized test, active substance use/abuse, vision or hearing impairments, and health and/or medication-related concerns. It is expected that the request for testing may include information regarding prior medical screening and assessment, prior intervention for the given diagnosis, an explanation pertaining to why the clinical evaluation was inconclusive, and a statement regarding the need for neuropsychological testing to clarify the diagnosis. Tests must be standardized and validated measures recognized by the scientific and professional community as a national standard for professional practice. Practitioners administering neuropsychological batteries should practice within their scope and be credentialed in a matter consistent with the expectations of the North Carolina Psychology Board.

Psychological/Developmental/Neuropsychological Testing

Providers should be prepared to provide Alliance with the following information when requesting psychological, developmental and/or neuropsychological testing:

  • The reason testing is medically necessary (e.g. differential diagnosis, atypical symptomatology, prior/current mental health treatment is ineffective). Information should be provided to explain why a clinical evaluation was inconclusive and why testing is needed to clarify the diagnosis.
  • Clinical information relevant to the referral for testing and source of referral.
  • The specific names of the standardized, validated tests planned for the evaluation (Clinical Coverage Policy 8 C).
  • Information regarding prior mental health treatment and other interventions.
  • Information pertaining to prior testing/evaluation (tests, dates, results).
  • Justification for the medical necessity of further testing if prior testing has been completed.

Medical Necessity

Medical necessity for testing may be met in the following cases:

  • Best practice clinical intervention has not been effective.
  • Differential diagnosis is indicated to develop a more effective treatment plan.
  • The individual has a medical or neurological condition and has been referred by a physician for further assessment after being evaluated by the MD.
  • An individual presents with concerns regarding possible Intellectual/Developmental Disability and testing is needed for specialized services (Innovations).
  • Testing related to the treatment of pain or as a component of a pre-surgical evaluation may be considered medically necessary if consistent with the expectations per policy.
Psychological, developmental and neuropsychological testing requests may not meet medical necessity if:
  • Service is not considered consistent with generally accepted standards of practice or supported by credible research demonstrating the service will have a measurable and beneficial health outcome for the enrollee.
  • Tests are not standardized, valid measures nationally recognized by licensed practitioners in the field.
  • Requests are for educational placement/services (e.g., IEP), career/vocational, sports, camp, marriage, adoption, or insurance purposes.
  • Requests are for judicial or legal proceedings such as Guardianship (Clerk of the Court and/or the NC Division of Aging and Adult Services) or parental competency (Department of Social Services (DSS) and/or the court system).
  • The evaluation is for Disability as these evaluations are adjudicated through North Carolina Disability Determination Services (DDS)
  • The enrollee has not had a diagnostic evaluation by a licensed mental health practitioner.
  • The enrollee presents with symptoms of ADHD and has not had a thorough evaluation by a psychiatrist or prior screening using questionnaires or rating scales.  Requests for testing for ADHD should include an explanation of the reason the initial evaluation (e.g., by a licensed mental health practitioner and/or physician) was insufficient.
  • Testing for the primary purpose of titrating medications.
  • Routine/periodic testing without clinical justification will not meet medical necessity.  Exemption: It is noted that children/adolescents with I/DD diagnoses will need updated testing every 3 years to determine I/DD eligibility, and adults entering waiver services must have evaluations within the past 5 years.
  • The enrollee is actively abusing substances, in acute withdrawal, or recently entered recovery as the testing results may not be valid.
  • If mental health symptoms are causing significant impairment (e.g., enrollee is actively psychotic, manic, aggressive, etc.) such that the testing results may not be valid.
  • Testing has been previously completed and there is no clinical justification for further testing (e.g., TBI, medical condition, developmental changes, or other factors that render the previous evaluation inaccurate).
  • There is no indication based on Clinical Coverage Policy/Service Definition that testing is required to access the covered service.

Psychological Testing vs. Neuropsychological Testing

Providers requesting neuropsychological testing/evaluations should provide statements explaining why neuropsychological testing is necessary for the purpose of exploring questions related to the enrollee’s diagnosis and for treatment recommendations.  Neuropsychological testing is considered medically necessary for the assessment of cognitive impairment due to medical or psychiatric conditions. Psychological testing should be summarized in a report reflecting psychological testing has been completed (“Psychological Evaluation”).  Neuropsychological testing should be summarized in a report reflecting neuropsychological testing has been completed (“Neuropsychological Evaluation”). Neuropsychological testing should not be requested when the clinical questions can be addressed through a psychological evaluation.

References:
North Carolina Psychology Practice Act
Clinical Coverage Policy 8C